NCT00568646View on ClinicalTrials.gov

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

MKC-1

Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY